Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 271-277

  Fisher, G ^a   Yang, Z H ^a   Kudahetti, S ^b   Moller H ^c   Scardino, P ^d   Cuzick, J ^a   Berney, D M ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ki 67; Localised prostate cancer; Needle biopsy; Prognostic factors

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER CELL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CELLS; CONSERVATIVE TREATMENT; GLEASON SCORE; HAZARD RATIO; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY; UNIVARIATE ANALYSIS;

AGED; BIOPSY, NEEDLE; CELL PROLIFERATION; COHORT STUDIES; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM GRADING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873724597     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.598     Document Type: Article

References (29)

1. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J (2009) Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 100(6): 888-893.
2. Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A (2002) Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 8(5): 1148-1154. (Pubitemid 34517652)
3. Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S. on behalf of the Transatlantic Prostate Group (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106: 1095-1099.
4. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino P. Transatlantic Prostate Group (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186-1194. (Pubitemid 44658482)
5. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake 2nd DD, Wagner S, Gutin A, Lanchbury JS, Stone S. Transatlantic Prostate Group (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol 12(3): 245-255.
6. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW (2008) p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: A prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology 71: 933-937.
7. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, SotirioüC, Smith IE, Viale G, Zujewski JA, Hayes DF. International Ki-67 in Breast Cancer Working Group (2011) Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22): 1656-1664.
8. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9): 1228-1242. (Pubitemid 41232997)
9. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13): 981-990. (Pubitemid 34814727)
10. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla Palma P, Barbareschi M (2002) Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. J Pathol 198(3): 292-299.
11. Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26(3): 243-250.
12. Havelund BM, Olsen DA, Andersen RF, Spindler KL, Brandslund I, Jakobsen A, Soerensen FB (2012) The influence of tissue ischemia on biomarker expression in colorectal cancer. Appl Immunohistochem Mol Morphol; e-pub ahead of print 10 October 2012.
13. Jhavar S, Bartlett J, Kovacs G, Corbishley C, Dearnaley D, Eeles R, Khoo V, Huddart R, Horwich A, Thompson A, Norman A, Brewer D, Cooper CS, Parker C (2009) Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis 12(2): 143-147.
14. Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A (2009) MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 27(19): 3177-3184.
15. Kristiansen G (2012) Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 60(1): 125-141.
16. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122(3): 595-602. (Pubitemid 350308951)
17. Li R, Heydon K, Hammond ME, Grignon DJ, Roach 3rd M, Wolkov HB, Sandler HM, Shipley WU, Pollack A (2004) Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 10(12 Pt 1): 4118-4124. (Pubitemid 38812491)
18. Lophatananon A, Tyndale-Biscoe S, Malcolm E, Rippon HJ, Holmes K, Firkins LA, Fenton M, Crowe S, Stewart-Brown S, Gnanapragasam VJ, Muir KR (2011) The James Lind Alliance approach to priority setting for prostate cancer research: An integrative methodology based on patient and clinician participation. BJÜInt 108: 1040-1043.
19. McCarthy F, Dennis N, Flohr P, Jhavar S, Parker C, Cooper CS (2011) Highdensity tissue microarrays from prostate needle biopsies. J Clin Pathol 64: 88-90.
20. Mengel M, von Wasielewski R, Wiese B, Ru?diger T, Mu?ller-Hermelink HK, Kreipe H (2011) Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. Diagn Pathol 6(Suppl 1): S7.
21. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T (2003) Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97(7): 1630-1638. (Pubitemid 36350706)
22. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach 3rd M, Shipley WU, Hanks GE, Sandler HM (2004) Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 22(11): 2133-2140. (Pubitemid 41095146)
23. Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26(3): 312-319. (Pubitemid 34184454)
24. Rubio J, Ramos D, López-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S, Llombart-Bosch A (2005) Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 48(5): 745-751. (Pubitemid 41495372)
25. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, Blute ML, Zincke H (2002) Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 26(4): 431-439. (Pubitemid 34280115)
26. Stattin P, Damber JE, Karlberg L, Bergh A (1997) Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 157(1): 219-222. (Pubitemid 26414962)
27. Vergis R, Corbishley CM, Thomas K, Horwich A, Huddart R, Khoo V, Eeles R, Sydes MR, Cooper CS, Dearnaley D, Parker C (2010) Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int J Radiat Oncol Biol Phys 78: 35-41.
28. WHO. International Statistical Classification of Diseases and Related Health Problems. 10th revision, 4th edition (2010) ISBN 978 92 4 154834 2 http://www.who.int/classifications/icd/ICD10Volume2-en-2010.pdf. \\
29. Zellweger T, Gu?nther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, Ru?fenacht H, Bachmann A, Gasser TC, Mihatsch MJ, Bubendorf L (2009) Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 124(9): 2116-2123.